Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Nam	e of entity	ABN/ARSN		
Sig	ma Pharmaceuticals Limited		15 088 417 403	
We	(the entity) give ASX the following	information.		
Inf	ormation about buy-back			
1	Type of buy-back	On-market buy-back		
2	Date Appendix 3C was given to ASX		3D dated 2 October	
То	eal of all aboves/units bought	Lada a Canalada a		
	cal of all shares/units bought we been received, before, and		which acceptances	
			Previous day	
		on, previous day	_	
hav	Number of shares/units bought back or if buy-back is an equal access scheme, in relation to which acceptances have been	on, previous day Before previous day	Previous day	

		Before previous day		s day	Previous day
5	If buy-back is an on-market buy-back	Highest \$0.8525	price	paid:	Highest price paid: \$0.8400
		Lawret		ar a tala	Lowest price paid: \$0.8250
		\$0.5600	price	paid:	Highest price allowed under rule 7.33: \$0.9065

How many shares/units may still be bought back?

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

Print name:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here: Date: 3 June 2015

(Director/Company secretary)

SUE MORGAN

== == == == ==